<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149902</url>
  </required_header>
  <id_info>
    <org_study_id>631</org_study_id>
    <nct_id>NCT01149902</nct_id>
  </id_info>
  <brief_title>Study of Chemo-Immunotherapy in Head and Neck Cancer Patients</brief_title>
  <official_title>Phase I Study of Chemo-Immunotherapy in Patients With Relapsed and Refractory Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Yamanashi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Yamanashi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and feasibility of Chemo-Immunotherapy using
      cyclophosphamide, docetaxel, OK-432, and autologous immature dendritic cells for patients
      with relapsed and refractory head and neck squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and feasibility of chemo-immunotherapy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number and function of immune effector cells in treated patients</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cyclophosphamide, Docetaxel, Dendritic cells, OK-432</intervention_name>
    <description>Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients with relapsed and refractory head and neck squamous cell carcinoma

          2. 20 years and older

          3. ECOG performance status 0-1

          4. More than 4 weeks must have elapsed from the time of radiation therapy and the last
             dose of chemotherapy

          5. Tumor lesions are accessible to intratumoral dendritic cells injection

          6. Patients who are able to do oral ingestion

          7. Patients must have normal organ and marrow functions as follows:

               -  Hb&gt;9.0 mg/dl

               -  Ht&gt;25%

               -  WBC&gt;4000/mm3

               -  Platelet count&gt;100,000/mm3

               -  T-Bil&lt;1.5mg/dl

               -  GOT&lt;x2.5 institutional upper limit of normal

               -  GPT&lt;x2.5 institutional upper limit of normal

               -  Creatinin&lt;1.5mg/dl

          8. signed informed consent

        Exclusion Criteria:

          1. Less than 20 years

          2. Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV.

          3. Patients with clinically active infection

          4. Patients with uncontrolled concurrent illness including cardiovascular disease,
             pulmonary disease, and bleeding tendency

          5. Concomitant malignant diseases, brain metastases

          6. Psychiatric illness

          7. Treatment with steroids

          8. Decision of unsuitableness by physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hiroki Ishii, MD</last_name>
    <phone>+81-55-273-6769</phone>
    <email>ishiih@yamanashi.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Umiversity of Yamanashi Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Yamanashi</state>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroki Ishii, MD</last_name>
      <phone>+81-55-273-6769</phone>
      <email>ishiih@yamanashi.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Keisuke Masuyama, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <last_update_submitted>August 23, 2011</last_update_submitted>
  <last_update_submitted_qc>August 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Keisuke Masuyama, Professor</name_title>
    <organization>Department of Otolaryngology-Head and Neck Surgery, University of Yamanashi, Faculty of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Picibanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

